Loading patent…
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsArthur Groy, Aidan Hancock, Matthew Robert Sender, Brandon James Turunen, Cunyu Zhang, Craig Leach
Estimating the term…
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
An antibody-drug conjugate comprising:
The antibody-drug conjugate of any one of the preceding claims, wherein the ratio of cytotoxic agent to antibody or antigen-binding fragment thereof is in a range of about 1:1 to about 10:1.
The antibody-drug conjugate of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) as set forth in SEQ ID NO:
The antibody-drug conjugate of any one of the preceding claims, wherein the antibody comprises a heavy chain as set forth in SEQ ID NO:
A bispecific antibody or bispecific antigen binding fragment thereof comprising a cotinine binding domain and a CD3 binding domain.
Dependencies are inferred from the claim text.